The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Research Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Research Site
Essen, Ruhr, Germany
Research Site
Herne, Ruhr, Germany
Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam
Time frame: assessed at each visit
Pharmacokinetics (PK) of AZD2171 alone and in combination with AZD0530
Time frame: assessed at each visit
Safety and efficacy
Time frame: assessed at each visit
Genetic variation of pathways targeted by AZD2171 and AZD0530
Time frame: assessed during study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.